EW · NYSE
Edwards Lifesciences Corporation
$89.07 -1.03 (-1.14%)
Company overview
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, critical care, and surgical monitoring worldwide. The company offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves, as well as transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. It also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally invasive therapy. In addition, Edwards Lifesciences offers surgical structural heart solutions, including the INSPIRIS aortic surgical valve, KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients requiring replacement of the valve, root, and ascending aorta, and the HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Exchange
- NYSE
- Market cap
- $51.3B
- Employees
- 15,800
- Headquarters
- Irvine, CA
- Website
- edwards.com
- CEO
- Bernard J. Zovighian
- Listed
- March 27, 2000
- P/E
- 47.13
- Dividend yield
- 0.00%
Company financials
- Revenue
- $6.3B
- Gross profit
- $4.9B
- Operating income
- $1.7B
- EBITDA
- $1.4B
- Net income
- $1.1B
- EPS
- $1.89
- Total assets
- $13.3B
- Total debt
- $703M
- Gross margin
- 78.01%
- Net margin
- 17.34%
- Earnings yield
- 2.12%
Showing FY 2025
EW
1D
NYSE
O88.64H90.19L88.28C90.09+1.69 (+1.91%)Vol3.05M